Roche faces another setback in Alzheimer's as gantenerumab fails phase 3 trials, MorphoSys plunges 32%

Nov. 14, 2022 4:51 AM ETRoche Holding AG (RHHBY), RHHBFBIIB, ESALY, ESALF, MORBy: Ravikash, SA News Editor11 Comments

Sunset view of riverside of Rhine dominated by the Roche tower in Switzerland

trabantos/iStock via Getty Images

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said its medicine gantenerumab did not meet the main goal of slowing clinical decline in two phase 3 studies in people with early Alzheimer's disease.

The results mark a second setback for the Swiss

Recommended For You

Comments (11)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.